NDA 200403 · Hospira INC
Hydromorphone Hydrochloride
Hydromorphone Hydrochloride · Injection
Last checked: Nov 19, 2026Latest source record: Dec 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2011
Dec 1, 2011
Approved uses
1
Original approval plus efficacy supplements
Registered trials
290
61 Phase 3, 22 recruiting
FAERS reports
12,457
11,594 serious, 2,862 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF HYDROMORPHONE HYDROCHLORIDE INJECTION WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF HYDROMORPHONE HYDROCHLORIDE INJECTION See full prescribing information for complete boxed warning . • Hydromorphone Hydrochloride Injection exposes users to risks of addiction, abuse, and misuse, which can lead to overdose and death. Assess patient's risk before prescribing and reassess regularly for these behaviors and conditions. ( 5.1 ). • Serious, life-threatening, or fatal respiratory depression may occur with use of Hydromorphone Hydrochloride Injection, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of Hydromorphone Hydrochloride Injection are essential. ( 5.2 ). • Concomitant use of opioids with benzodiazepines or other central nervous...
What it is approved for
From the label in effect Feb 4, 2026.
Hydromorphone Hydrochloride Injection is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Hydromorphone Hydrochloride Injection is an opioid agonist indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. ( 1 ) Limitations of Use : Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration and persist over the course of therapy, reserve opioid analgesics, including Hydromorphone Hydrochloride Injection, for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. ( 1 , 5.1 ) Limitations of Use Because of the risks of addiction, abuse, misuse , overdose, and death , which can occur at any dosage or duration and persist over the course of therapy [see Warnings and Precautions (5.1) ] , reserve opioid analgesics, including Hydromorphone Hydrochloride Injection , for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain.
Mechanism: Hydromorphone is a full opioid agonist and is relatively selective for the mµ-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of hydromorphone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with morphine. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory and CNS depression. The precise mechanism of the analgesic action is unknown. However, specific CNS opioid receptors for endogenous compounds with opioid-like...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 1, 2011 Original approval · Type 7 - Drug Already Marketed without Approved NDA LabelSummary ReviewLetter
5 products under this application
- HYDROMORPHONE HYDROCHLORIDE · HYDROMORPHONE HYDROCHLORIDE 0.25MG/0.5ML · INJECTABLE, INJECTION · Prescription
- HYDROMORPHONE HYDROCHLORIDE · HYDROMORPHONE HYDROCHLORIDE 4MG/ML · INJECTABLE, INJECTION · Prescription · TE AP
- HYDROMORPHONE HYDROCHLORIDE · HYDROMORPHONE HYDROCHLORIDE 1MG/ML · INJECTABLE, INJECTION · Prescription · TE AP
- HYDROMORPHONE HYDROCHLORIDE · HYDROMORPHONE HYDROCHLORIDE 0.5MG/0.5ML · INJECTABLE, INJECTION · Prescription
- HYDROMORPHONE HYDROCHLORIDE · HYDROMORPHONE HYDROCHLORIDE 2MG/ML · INJECTABLE, INJECTION · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Hydromorphone" as an intervention, any sponsor and status, largest first.
Vanderbilt UniversityAcademic, hospital or other
NCT02625181 · 27,034 participants · Start Jul 2016 · Primary completion Nov 2, 2017
Drug: Propofol; Sevoflurane and 28 more · For: Postoperative Nausea and Vomiting
Sites: Nashville, Tennessee
- Patient-controlled Intravenous Analgesia Combined With Different Opioid Receptors for Gastrointestinal SurgeryPivotal-lookingCompleted
Xijing HospitalAcademic, hospital or other
NCT05576675 · 4,342 participants · Start May 1, 2018 · Primary completion Mar 31, 2022
Drug: sufentanil + nalbuphine; Sufentanil and 1 more · For: Gastrointestinal Surgery
Sites: XIan, China
- Recommendations of Enhanced Recovery Interventions for Patient's Clinical Team and Collection of Associated DataPivotal-lookingCompleted
Jennifer Holder-MurrayAcademic, hospital or other
NCT04606264 · 3,395 participants · Start May 15, 2023 · Primary completion Mar 21, 2025
Drug: Neuraxial Analgesia; Regional Block 1: Paravertebral and 6 more · For: Perioperative Optimization
Sites: Pittsburgh, Pennsylvania · 3 sites in all
- MAST Trial: Multi-modal Analgesic Strategies in TraumaPivotal-lookingCompleted
The University of Texas Health Science Center, HoustonAcademic, hospital or other
NCT03472469 · 1,561 participants · Start Apr 2, 2018 · Primary completion Jul 3, 2019
Drug: Acetaminophen IV/PO; Acetaminophen PO and 9 more · For: Nonspecific Pain Post Traumatic Injury
Sites: Houston, Texas
- Determining the Effect of an "Alternate Recovery Protocol" Versus Current Standard of Care After Cesarean SectionPivotal-lookingTerminated
Brest, Norman A., M.D.Academic, hospital or other
NCT03330119 · 1,494 participants · Start Oct 4, 2017 · Primary completion Jun 20, 2018
Drug: Alternate Management; Control · For: Pregnancy Related; Narcotic Use
Sites: Wynnewood, Pennsylvania
- IV PCA With or Without Continuous Dose vs Oral Opioid to Maintain Analgesia for Severe Cancer Pain After Successful TitrationPivotal-lookingCompleted
Fujian Cancer HospitalGovernment (non-federal)
NCT04785768 · 1,372 participants · Start Jul 1, 2021 · Primary completion May 1, 2024
Drug: Hydromorphone Hydrochloride Injection; Hydromorphone Hydrochloride Injection and 1 more · For: Cancer Pain
Sites: Fuzhou, China
- Effect of Tramadol in Prevention of Postpartum DepressionPivotal-lookingCompleted
Xinqiao Hospital of ChongqingAcademic, hospital or other
NCT03309163 · 1,230 participants · Start Oct 9, 2017 · Primary completion Jun 13, 2019
Drug: Tramadol; Hydromorphone and 1 more · For: Caesarean Section
Sites: Chongqing, China
- Intravenous Remifentanil for Labor AnalgesiaPivotal-lookingCompleted
Nanjing Medical UniversityAcademic, hospital or other
NCT00710086 · 1,000 participants · Start Jul 2008 · Primary completion Sep 2009
Drug: Hydromorphone; Remifentanil · For: Labor Pain
Sites: Nanjing, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug dependence2,688
- pain2,511
- drug ineffective2,127
- off label use1,893
- overdose1,828
- nausea1,796
- drug hypersensitivity1,720
- vomiting1,560
- headache1,473
- fatigue1,312
- dyspnoea1,213
- pneumonia1,193
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 43 |
| 2005 | 39 |
| 2006 | 43 |
| 2007 | 45 |
| 2008 | 41 |
| 2009 | 37 |
| 2010 | 97 |
| 2011 | 20 |
| 2012 | 114 |
| 2013 | 55 |
| 2014 | 60 |
| 2015 | 111 |
| 2016 | 215 |
| 2017 | 309 |
| 2018 | 863 |
| 2019 | 1,007 |
| 2020 | 846 |
| 2021 | 1,746 |
| 2022 | 2,409 |
| 2023 | 1,232 |
| 2024 | 1,392 |
| 2025 | 1,077 |
| 2026 | 655 |
Recalls
3 FDA enforcement reports for this application.
Aug 22, 2017 · Class II · Terminated
Lack of sterility assurance: resulting from use of a damaged sterilizing filter for nitrogen used in the manufacturing process.
Aug 15, 2012 · Class I · Terminated
Superpotent (Single Ingredient) Drug: The prefilled cartridge unit has been found to be overfilled and contain more than the 1 mL labeled fill volume.
May 12, 2012 · Class I · Terminated
Superpotent (Single Ingredient) Drug: Some of the prefilled cartridge units have been found to be overfilled and contain more than the 1 mL labeled fill volume.
Shortages
FDA's drug shortage list.
Current · updated Nov 9, 2026
Hydromorphone Hydrochloride, Injection, 2 mg/1 mL Syringes (NDC 0409-1312-30).
Current · updated Nov 9, 2026
Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 0409-1283-37). Other
Current · updated Nov 9, 2026
Hydromorphone Hydrochloride, Injection, 4 mg/1 mL Syringes (NDC 0409-1304-31).
Current · updated Nov 9, 2026
Hydromorphone Hydrochloride, Injection, 1 mg/1 mL Syringes (NDC 0409-1283-31). Demand increase for the drug
Current · updated Nov 9, 2026
Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0409-1312-36). Other
Current · updated Nov 9, 2026
Hydromorphone Hydrochloride, Injection, 0.25 mg/ 0.5 mL NexJect™ Single-dose Syringe Luer Lock (no needle) (NDC 0409-1805-01). Other
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- 2025 guideline update to acute treatment of migraine for adults in the emergency department: The American Headache Society evidence assessment of parenteral pharmacotherapies.
Robblee J, Minen MT, Friedman BW, et al. · Headache 2026 · Systematic Review, Meta-Analysis
- Effect of Intraoperative Esketamine Infusion on Postoperative Sleep Disturbance After Gynecological Laparoscopy: A Randomized Clinical Trial.
Qiu D, Wang XM, Yang JJ, et al. · JAMA Netw Open 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Investigational Drugs for the Treatment of Postherpetic Neuralgia: Systematic Review of Randomized Controlled Trials.
Huerta MÁ, Garcia MM, García-Parra B, et al. · Int J Mol Sci 2023 · Systematic Review
- Opioids for cancer pain - an overview of Cochrane reviews.
Wiffen PJ, Wee B, Derry S, et al. · Cochrane Database Syst Rev 2017 · Research Support, Non-U.S. Gov't, Systematic Review
- Shifting Views on Cancer Pain Management: A Systematic Review and Network Meta-Analysis.
Imkamp MSV, Theunissen M, Viechtbauer W, et al. · J Pain Symptom Manage 2024 · Systematic Review, Network Meta-Analysis
- Equianalgesic potency ratios of opioids used in patient-controlled analgesia: A network meta-analysis.
Dinges HC, Schubert AK, Rücker G, et al. · J Opioid Manag 2022 · Systematic Review, Network Meta-Analysis
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.